Price Prediction

Moderna (MRNA) Stock Price Prediction: Analyst targets improved, but price action is still fragile

Moderna (MRNA) traded at $198.91, down 4.45% over 24 hours, while key moving averages remain overhead and momentum is still weak. Analyst updates were mixed: JPMorgan lifted its target to $102, Mor...

Moderna (MRNA) Stock Price Prediction: Analyst targets improved, but price action is still fragile

What happened

Moderna (MRNA) is still digesting a sharp pullback. The shares were last quoted at $198.91, down 4.45% on the day, with the 24-hour range stretching from $210.22 to $192.24. That leaves the stock just above its Bollinger lower band at $189.82, but still below the 7-day, 20-day, 50-day, 12-day EMA and 26-day EMA.

That setup matters because it shows a stock that has already de-rated from the recent peak, yet has not regained trend control. The short-term structure is still distributional, with MA7 below MA20 and price trading well under the 20-day average of $231.81.

Analyst backdrop is mixed, not uniformly bullish

The latest analyst notes point in different directions. JPMorgan raised its target to $102 from $77 while keeping an Underweight rating, citing Moderna’s analyst day, updated 2026 guidance and the company’s 2027-plus expense framework. Morgan Stanley kept an Equal-Weight rating and lifted its target to $200 from $95. Piper Sandler was more constructive, raising its target to $305 from $230 and maintaining Overweight.

Broader survey data from stockanalysis.com shows 23 analysts with a consensus Hold rating and an average price target of $164.53. That sits below the current share price, which is a reminder that the market is trading above the average analyst view even after the recent decline.

Fundamentals: the earnings profile improved, but the burden is still on execution

Moderna’s own Nov. 6 update said third-quarter revenue rose 29% to $1.3 billion, cash costs fell 10% to $1.0 billion, and the company was profitable. It also lifted full-year guidance, now expecting revenue growth of 15% to 25%, above its prior outlook of up to 10% growth versus 2025. The company also said it was tracking toward its first year of revenue growth since 2022.

That is the key fundamental change here: the market is no longer dealing with a simple post-pandemic compression story. Instead, it is judging whether Moderna can sustain revenue growth while keeping costs contained and converting pipeline progress into durable operating leverage. Piper Sandler also cited third-quarter product sales of $1.27 billion, cash of $8 billion and long-term debt of $3.19 billion, which it said should support a return to profitability in 2028.

Derivatives and positioning: participation is rising, but the tape is not clean

Binance perpetual futures show funding at 0.0014%, which is neutral, so there is no strong sign that one side is aggressively paying to stay positioned. Open interest is 12,371.79 contracts, with open interest value at $2,985,798 and a 24-hour increase of 21.42%. That is a meaningful build in positioning, but it does not tell you direction by itself.

The long/short ratios are only slightly constructive. Global accounts are 52.4% long versus 47.6% short, while top-trader accounts are 50.6% long versus 49.4% short. Against that, taker flow is still leaning bearish, with the buy/sell ratio at 0.8010 and aggressive selling pressure in the most recent hour.

Technical read: near support, not yet back in trend

The chart is stretched below trend and still vulnerable. The stock is below the 7-day SMA at $211.19, the 50-day SMA at $219.28, the 12-day EMA at $219.10 and the 26-day EMA at $222.77. The 20-day SMA at $231.81 remains a far more important ceiling than a support.

Momentum is weak but not washed out. RSI at 39.67 is neutral-to-soft, MACD is negative at -3.6722, and stochastic readings of 7.51 for %K and 6.00 for %D show the stock near the lower end of its recent range. The key pivot is $200.46. Below that, immediate support sits at $190.69, then strong support at $182.48. On the upside, immediate resistance is $208.67, with stronger resistance at $218.44.

What would change the setup

For bulls, the first task is simple: hold the $190.69 area and reclaim $200.46, then push back through $208.67. That would start to repair the short-term damage and signal that the recent pullback is becoming a consolidation rather than a breakdown.

For bears, failure to defend the lower band area around $189.82 and the nearby $190.69 support would leave $182.48 exposed. The recent build in open interest would then become a risk factor rather than a positive signal, because more position size in a weak tape can amplify downside if sellers stay in control.

Sign in to save this article Free account: build your research collection and return to read it anytime.